- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Glatiramer acetate (GA), Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 32 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 282
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapse Remitting Multiple Sclerosis
- Interventions
- Blood Draw
- Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- natalizumab, fingolimod
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Port Charlotte, Florida + 9 more
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Motivational Interviewing-Cognitive Behavioral Therapy, Brief Education
- Behavioral
- Lead sponsor
- University of Missouri, Kansas City
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Kansas City, Missouri • West Orange, New Jersey
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
- Interventions
- There is no intervention in this study
- Other
- Lead sponsor
- ProgenaBiome
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Ventura, California
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Multiple Sclerosis
- Interventions
- ACT-128800 Dose 1, Placebo, ACT-128800 Dose 2, ACT-128800 Dose 3
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 25
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 22 more
- Conditions
- Multiple Sclerosis
- Interventions
- Wahls Paleo Plus, Wahls Diet
- Other
- Lead sponsor
- Terry L. Wahls
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Cladribine, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 867 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 17
- States / cities
- Boulder, Colorado • Atlanta, Georgia • Chicago, Illinois + 14 more
- Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
- Interventions
- BeCare application
- Device
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
- Interventions
- Serum Neurofilament Light
- Diagnostic Test
- Lead sponsor
- Dent Neuroscience Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Amherst, New York
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Ofatumumab, Disease modifying treatment (DMT)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Chandler, Arizona + 34 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Fatigue
- Interventions
- TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY], Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Tovaxin Autologous T cell vaccine, Placebo
- Biological
- Lead sponsor
- Opexa Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 33
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 29 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- ALKS 8700, Dimethyl Fumarate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 57
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
- Conditions
- Multiple Sclerosis
- Interventions
- Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate)
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Brookline, Massachusetts
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Dimethyl Fumarate
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Seattle, Washington
- Conditions
- Multiple Sclerosis
- Interventions
- MRI
- Other
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Interventions
- Not listed
- Lead sponsor
- LAPIX Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Chevy Chase, Maryland • New York, New York + 1 more
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
- Interventions
- wearable focal vibration therapy
- Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Gainesville, Florida
- Conditions
- RELAPSING REMITTING MULTIPLE SCLEROSIS
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Multiple Sclerosis
- Interventions
- Copaxone®
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 861 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 15
- States / cities
- Cullman, Alabama • Carmichael, California • Atlanta, Georgia + 11 more
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- BAF312, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 16
- States / cities
- Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more